5-MeO-DMTHalberstadt, Adam L. "Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N, N-dimethyltryptamine." Pharmacology Biochemistry and Behavior 143 (2016): 1-10.
Guchhait, R. B. "Biogenesis of 5‐methoxy‐N, N‐dimethyltryptamine in human pineal gland." Journal of neurochemistry 26.1 (1976): 187-190.
Shen, Hong-Wu, et al. "Psychedelic 5-methoxy-N, N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions." Current drug metabolism 11.8 (2010): 659-666.
Furst, Peter T. Symbolism and psychopharmacology: the toad as earth mother in Indian America. Sociedad mexicana de antropologia, 1972.
AyahauscaRiba, Jordi, Antoni Rodríguez-Fornells, and Manel J. Barbanoj. "Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively." Psychopharmacology 165.1 (2002): 18-28.
Fotiou, Evgenia. From medicine men to day trippers: Shamanic tourism in Iquitos, Peru. Diss. UNIVERSITY OF WISCONSIN-MADISON, 2010.
Naranjo, Plutarco. "Hallucinogenic plant use and related indigenous belief systems in the Ecuadorian Amazon." Journal of ethnopharmacology 1.2 (1979): 121-145.
Queiroz, Marcos Marçal Ferreira, et al. "LC–MS/MS Quantitative Determination of Tetrapterys mucronata Alkaloids, a Plant Occasionally used in Ayahuasca Preparation." Phytochemical Analysis 26.3 (2015): 183-188.
Hashimoto, Yohei, and Kazuko Kawanishi. "New alkaloids from Banisteriopsis caapi." Phytochemistry 15.10 (1976): 1559-1560.
Palhano-Fontes, Fernanda, et al. "The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network." Plos one 10.2 (2015): e0118143.
Beta CarbolinesFrost, Danielle, et al. "β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites." PLoS One 6.5 (2011): e19264.
Airaksinen, M. M., and I. Kari. "Beta-carbolines, psychoactive compounds in the mammalian body. Part I: Occurrence, origin and metabolism." Medical biology 59.1 (1981): 21-34.
Airaksinen, M. M., and I. Kari. "beta-Carbolines, psychoactive compounds in the mammalian body. Part II: Effects." Medical biology 59.4 (1981): 190-211.
MacInnes, Nicholas, and Sheila L. Handley. "Characterization of the discriminable stimulus produced by 2‐BFI: effects of imidazoline I2‐site ligands, MAOIs, β‐carbolines, agmatine and ibogaine." British journal of pharmacology 135.5 (2002): 1227-1234.
McIsaac, William M., et al. "Chromatography of β-carbolines." Journal of Chromatography A 31 (1967): 446-454.
O'hearn, E., and M. E. Molliver. "Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline." Neuroscience 55.2 (1993): 303-310.
Flattery, David Stophlet, and Martin Schwartz. Haoma and harmaline: the botanical identity of the Indo-Iranian sacred hallucinogen" soma" and its legacy in religion, language, and Middle-Eastern folklore. Vol. 21. Univ of California Press, 1989.
Harrington, N. (2012). Harmala Alkaloids as Bee Signaling Chemicals. Journal Of Student Research, 1(1), 23-32.
Touiki, Khalid, et al. "Harmane inhibits serotonergic dorsal raphe neurons in the rat." Psychopharmacology 182.4 (2005): 562-569.
Bourogaa, Ezzeddine, et al. "Hepatoprotective activity of Peganum harmala against ethanol-induced liver damages in rats." Archives of physiology and biochemistry 121.2 (2015): 62-67.
Miralles, Antonio, et al. "High-affinity binding of β-carbolines to imidazoline I 2B receptors and MAO-A in rat tissues: Norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain." European journal of pharmacology 518.2 (2005): 234-242.
Herraiz, Tomas, and Carolina Chaparro. "Human monoamine oxidase is inhibited by tobacco smoke: β-carboline alkaloids act as potent and reversible inhibitors." Biochemical and biophysical research communications 326.2 (2005): 378-386.
George, Tony P., and Andrea H. Weinberger. "Monoamine oxidase inhibition for tobacco pharmacotherapy." Clinical pharmacology and therapeutics 83.4 (200
: 619.
Herraiz, Tomás, Hugo Guillén, and Vicente J. Arán. "Oxidative metabolism of the bioactive and naturally occurring β-carboline alkaloids, norharman and harman, by human cytochrome P450 enzymes." Chemical research in toxicology 21.11 (200
: 2172-2180.
Wichlinski, Lawrence J. "Possible involvement of an endogenous benzodiazepine receptor ligand of the inverse agonist type in the regulation of rapid-eye movement (REM) sleep: An hypothesis." Progress in Neuro-Psychopharmacology and Biological Psychiatry 20.1 (1996): 1-44.
Naranjo, Claudio. "Psychotropic properties of the harmala alkaloids." Ethnopharmacolologic Search for Psychoative Drugs (1967) 389-391.
Hassani, Lalla Mina Idrissi, Zahra Ferji, and Miloud El Hadek. "Quantitative and Qualitative Analysis by HPLC of Major Peganum harmala Alkaloids at Different Stages of Development." (2013).
Herraiz, Tomas. "Tetrahydro-β-carbolines, potential neuroactive alkaloids, in chocolate and cocoa." Journal of agricultural and food chemistry 48.10 (2000): 4900-4904.
Biosynthesis/Endogenous TryptaminesGuchhait, Ras B., and James E. Grau. "BIOSYNTHESIS OF S‐ADENOSYL‐L‐METHIONINE IN THE RAT PINEAL GLAND." Journal of neurochemistry 31.4 (197
: 921-925.
Guchhait, Ras B., and Andrew A. Monjan. "Circadian Rhythm in Pineal Methionine S‐Adenosyltransferase." Journal of neurochemistry 36.6 (1981): 2092-2093.
Forsström, J. Tuominen, J. Kärkkäinen, T. "Determination of potentially hallucinogenic N-dimethylated indoleamines in human urine by HPLC/ESI-MS-MS." Scandinavian journal of clinical and laboratory investigation 61.7 (2001): 547-556.
Gomes, U. R., A. C. Neethling, and B. C. Shanley. "ENZYMATIC N‐METHYLATION OF INDOLEAMINES BY MAMMALIAN BRAIN: FACT OR ARTEFACT?." Journal of neurochemistry 27.3 (1976): 701-705.
Reiter, Russel J., and Bruce A. Richardson. "Magnetic field effects on pineal indoleamine metabolism and possible biological consequences." The FASEB journal 6.6 (1992): 2283-2287.
Saavedra, Juan M., and Julius Axelrod. "Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro." Science 175.4028 (1972): 1365-1366.
Yu, Ai-Ming, et al. "Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6." Pharmacogenetics and Genomics 13.3 (2003): 173-181.
Yu, Ai-Ming, et al. "Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase." Pharmacogenetics and Genomics 13.6 (2003): 307-319.
Bottiglieri, Teodoro, Keith Hyland, and Edward H. Reynolds. "The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders." Drugs 48.2 (1994): 137-152.
Burchett, Scott A., and T. Philip Hicks. "The mysterious trace amines: protean neuromodulators of synaptic transmission in mammalian brain." Progress in neurobiology 79.5 (2006): 223-246.
Boarder, Michael R., and Richard Rodnight. "Tryptamine-N-methyltransferase activity in brain tissue: a re-examination." Brain research 114.2 (1976): 359-364.
BufotenineEmanuele, Enzo, et al. "Elevated urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia." Neuro Endocrinol Lett 31.1 (2010).
CannabisSmall, Ernest, Perry Y. Jui, and Leonard P. Lefkovitch. "A numerical taxonomic analysis of Cannabis with special reference to species delimitation." Systematic Botany (1976): 67-84.
DMTBarker, Steven A., Ethan H. McIlhenny, and Rick Strassman. "A critical review of reports of endogenous psychedelic N, N‐dimethyltryptamines in humans: 1955–2010." Drug testing and analysis 4.7-8 (2012): 617-635.
Gallimore, Andrew R., and Rick J. Strassman. "A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience." Frontiers in Pharmacology 7 (2016).
Frecska, Ede, et al. "A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity." Journal of Neural Transmission 120.9 (2013): 1295-1303.
GALLIMORE, ANDREW R. "Building Alien Worlds—The Neuropsychological and Evolutionary Implications of the Astonishing Psychoactive Effects of N, N-Dimethyltryptamine (DMT)." Journal of Scientific Exploration 27.3 (2013): 455-503.
GALLIMORE, ANDREW R. "Building Human Worlds - DMT and the Simulated Universe." PsyPress UK Journal 2015 Volume VI.
Servillo, Luigi, et al. "Citrus genus plants contain N-methylated tryptamine derivatives and their 5-hydroxylated forms." Journal of agricultural and food chemistry 61.21 (2013): 5156-5162.
Luke, David. "Discarnate entities and dimethyltryptamine (DMT): Psychopharmacology, phenomenology and ontology." Journal of the Society for Psychical Research 75.902 (2011): 26.
GALLIMORE, ANDREW R. "DMT and the Topology of Reality." Neurotransmissions: Psychedelic Essays from Breaking Convention, Strange Attractor Press 2015.
SZÁRA, STEPHEN. "DMT AT FIFTY." Neuropsychopharmacologia Hungarica 2007, IX/4; 201-205.
Jacob, Michael S., and David E. Presti. "Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine." Medical hypotheses 64.5 (2005): 930-937.
Wyatt, R. J., et al. "Gas chromatographic-mass spectrometric isotope dilution determination of N, N-dimethyltryptamine concentrations in normals and psychiatric patients." Psychopharmacologia 31.3 (1973): 265-270.
Vitale, Arturo A., et al. "In vivo long-term kinetics of radiolabeled N, N-dimethyltryptamine and tryptamine." Journal of Nuclear Medicine 52.6 (2011): 970-977.
Barker, Steven A., et al. "LC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate." Biomedical Chromatography 27.12 (2013): 1690-1700.
Riba, Jordi, et al. "Metabolism and urinary disposition of N, N‐dimethyltryptamine after oral and smoked administration: a comparative study." Drug testing and analysis 7.5 (2015): 401-406.
Carbonaro, Theresa M., and Michael B. Gatch. "Neuropharmacology of N, N-dimethyltryptamine." Brain research bulletin (2016).
Smith, Shaun. "N, N-Dimethyltryptamine and biological reductive accounts for religious and spiritual experiences." (2014).
Chu, Uyen B., et al. "Noncompetitive inhibition of indolethylamine-N-methyltransferase by N, N-dimethyltryptamine and N, N-dimethylaminopropyltryptamine." Biochemistry 53.18 (2014): 2956-2965.
Grammenos, Dionysios, and Steven A. Barker. "On the transmethylation hypothesis: stress, N, N-dimethyltryptamine, and positive symptoms of psychosis." Journal of Neural Transmission 122.6 (2015): 733-739.
Szabo, Attila, et al. "Psychedelic N, N-dimethyltryptamine and 5-methoxy-N, N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells." PloS one 9.8 (2014): e106533.
Acosta-Urquidi, Juan. "QEEG Studies of the Acute Effects of the Visionary Tryptamine DMT." Cosmos and History: The Journal of Natural and Social Philosophy 11.2 (2015): 115-129.
Mandel, L. R., et al. "The biosynthesis of dimethyltryptamine in vivo." Research communications in chemical pathology and pharmacology 16.1 (1977): 47-58.
SZÁRA, STEPHEN. "The DMT Story: An Interview with Stephen Szara."Social Pharmacology 3(3). (1989) 237-248.
Huszti, Z., and J. Borsy. "The effect of diethyltryptamine and its derivatives on monoamine oxidase." Biochemical pharmacology 13.8 (1964): 1151-1156.
Fontanilla, Dominique, et al. "The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator." Science 323.5916 (2009): 934-937.
Su, Tsung-Ping, Teruo Hayashi, and D. Bruce Vaupel. "When the endogenous hallucinogenic trace amine N, N-dimethyltryptamine meets the sigma-1 receptor." Science signaling 2.61 (2009): pe12.
DMT NexusRosino, Michael, and Annulla Linders. "Howard Becker in hyperspace: Social learning in an on-line drug community." Deviant Behavior 36.9 (2015): 725-739.
LSDCarhart-Harris, Robin L., et al. "Neural correlates of the LSD experience revealed by multimodal neuroimaging." Proceedings of the National Academy of Sciences 113.17 (2016): 4853-4858.
MDMARay, Thomas S. "Constructing the ecstasy of MDMA from its component mental organs: Proposing the primer/probe method." Medical hypotheses 87 (2016): 48-60.
Markowitz, J. S., S. D. Morrison, and C. Lindsay DeVane. "Drug interactions with psychostimulants." International clinical psychopharmacology 14.1 (1999): 1-18.
Sprague, JonE, and DavidE Nichols. "Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum." Psychopharmacology 118.3 (1995): 357-359.
McCANN, UNA D., and GEORGE A. RICAURTE. "Reinforcing subjective effects of (+/-) 3, 4-methylenedioxymethamphetamine (" ecstasy"
may be separable from its neurotoxic actions: clinical evidence." Journal of Clinical Psychopharmacology 13.3 (1993): 214-217.
MelatoninArendt, J. "Melatonin." Clinical endocrinology 29.2 (198
: 205-229.
der HEIJDEN, KRISTIAAN B. VAN, et al. "Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia." Journal of the American Academy of Child & Adolescent Psychiatry 46.2 (2007): 233-241.
Lissoni, P., et al. "Effects of tetrahydrocannabinol on melatonin secretion in man." Hormone and metabolic research 18.01 (1986): 77-78.
Sack RL, Lewy AJ, Blood ML, Stevenson J, Keith LD. Melatonin administration to blind people: phase advances and entrainment. J Biol Rhythms. 1991;6(3):249-61.
Ma, Xiaochao, et al. "Metabolism of melatonin by human cytochromes p450." Drug Metabolism and Disposition 33.4 (2005): 489-494.
Guardiola-lemaître B. Toxicology of melatonin. J Biol Rhythms. 1997;12(6):697-706.
PeyoteKapadia, Govind J., and M. B. E. Fayez. "Peyote constituents: chemistry, biogenesis, and biological effects." Journal of pharmaceutical sciences 59.12 (1970): 1699-1727.
Aragane, Masako, et al. "Peyote identification on the basis of differences in morphology, mescaline content, and trnL/trnF sequence between Lophophora williamsii and L. diffusa." Journal of natural medicines 65.1 (2011): 103-110.
El-Seedi, Hesham R., et al. "Prehistoric peyote use: Alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas." Journal of ethnopharmacology 101.1 (2005): 238-242.
Phalaris (Grass)FESTI, F., SAMORINI, G. Alcaloidi indolici psicoattivi nei generi Phalaris e Arundo (Graminaceae): una rassegna. «Annali Museo Civico Rovereto», vol. 9 (1994), pp. 239-287.
Parmar, Sohan Singh, and V. C. Brink. "Tryptamine levels in pasturage implicated in bovine pulmonary emphysema." Canadian Journal of Plant Science 56.1 (1976): 175-184.
Louis, Veronique, and Jonathan Negrel. "Tyramine hydroxycinnamoyl transferase in the roots of wheat and barley seedlings." Phytochemistry 30.8 (1991): 2519-2522.
Plant Use and AnalysisStafford, Gary I., Anna K. Jäger, and Johannes Van Staden. "African psychoactive plants." African Natural Plant Products: New Discoveries and Challenges in Chemistry and Quality (2009): 323-346.
Agurell, Stig, et al. "Alkaloids in certain species of Virola and other South American plants of ethnopharmacologic interest." Acta chemíca scandinavíca 23.3 (1969): 903-916.
Ghosal, S., S. Singh, and S. K. Bhattacharya. "Alkaloids of Mucuna pruriens chemistry and pharmacology." Planta Medica 19.01 (1971): 279-284.
Muszyńska, Bożena, et al. "Analysis of indole derivatives in methanolic extracts from mycelium of Agaricus bisporus cultured in vitro on liquid Oddoux medium." Folia Biologica et Oecologica 10.1 (2014): 66-72.
SOBIECKI, Jean-François. "A preliminary inventory of plants used for psychoactive purposes in southern African healing traditions." Transactions of the Royal society of South Africa 57.1-2 (2002): 1-24.
Edwards, Adam L., and Bradley C. Bennett. "Diversity of Methylxanthine Content inIlex cassine L. andIlex vomitoria Ait.: Assessing Sources of the North American Stimulant Cassina." Economic Botany 59.3 (2005): 275-285.
Nathan PJ. Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol (Oxford). 2001;15(1):47-54.
Tang, Ben-Qin, et al. "Iboga-Type Alkaloids from Ervatamia officinalis." Journal of natural products 77.8 (2014): 1839-1846.
Uebelhack, R., L. Franke, and H-J. Schewe. "Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava)." Pharmacopsychiatry 31.05 (199
: 187-192.
Alikaridis, F. "Natural constituents of Ilex species." Journal of Ethnopharmacology 20.2 (1987): 121-144.
Stermitz, Frank R., et al. "New and old phenanthrene derivatives from Oncidium cebolleta, a peyote-replacement plant." Journal of natural products 46.3 (1983): 417-423.
Santos, Ana Paula, and Paulo Roberto Hrihorowitsch Moreno. "Pilocarpus spp.: A survey of its chemical constituents and biological activities." Revista Brasileira de Ciências Farmacêuticas 40.2 (2004): 116-137.
Gericke, N., and A. M. Viljoen. "Sceletium—a review update." Journal of ethnopharmacology 119.3 (200
: 653-663.
Nair, Jerald J., and Johannes Van Staden. "Traditional usage, phytochemistry and pharmacology of the South African medicinal plant Boophone disticha (Lf) Herb.(Amaryllidaceae)." Journal of ethnopharmacology 151.1 (2014): 12-26.
Emboden, William A. "Transcultural use of narcotic water lilies in ancient Egyptian and Maya drug ritual." Journal of ethnopharmacology 3.1 (1981): 39-83.
PsilocybinGriffiths R, Richards W, Johnson M, Mccann U, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol (Oxford). 2008;22(6):621-32.
Carhart-Harris, Robin L., et al. "Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin." Proceedings of the National Academy of Sciences 109.6 (2012): 2138-2143.
Johnson MW, Garcia-romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol (Oxford). 2014;28(11):983-92.
Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol (Oxford). 2015;29(3):289-99.
Griffiths, Roland R., et al. "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance." Psychopharmacology 187.3 (2006): 268-283.
Kometer, Michael, et al. "Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations." Psychopharmacology 232.19 (2015): 3663-3676.
Berlant, Stephen R. "The entheomycological origin of Egyptian crowns and the esoteric underpinnings of Egyptian religion." Journal of ethnopharmacology 102.2 (2005): 275-288.
Russian OliveDr. Duke's Phytochemical and Enthnobotantical Databases - Chemicals found in Elaeagnus angustifolia
Abizov, E. A., and O. N. Tolkachev. "Dynamics of accumulation and distribution of β-carboline alkaloids in Elaeagnus species cultivated in Moscow Region." Pharmaceutical Chemistry Journal 45.10 (2012): 632-635.
Tolkachev, O. N., et al. "Phytochemical study of the bark of some plants of the Elaeagnaceae family as a natural source of β-carboline indole alkaloids." Pharmaceutical chemistry journal 42.11 (200
: 630-632.
Nikolaeva, A. G., A. P. Prokopenko, and P. E. Krivenchuk. "Spectrophotometric determination of the alkaloids of the β-carboline series in the bark of Elaeagnus angustifolia." Chemistry of Natural Compounds 6.6 (1970): 718-720.
SalviaMacLean, Katherine A., et al. "Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects." Psychopharmacology 226.2 (2013): 381-392.
Various NeuropharmacologyRaichle, Marcus E., et al. "A default mode of brain function." Proceedings of the National Academy of Sciences 98.2 (2001): 676-682.
Godwin, Douglass, Robert L. Barry, and René Marois. "Breakdown of the brain’s functional network modularity with awareness." Proceedings of the National Academy of Sciences 112.12 (2015): 3799-3804.
Luders, Eileen, et al. "Forever Young (er): potential age-defying effects of long-term meditation on gray matter atrophy." Deutsche Zeitschrift für Akupunktur 58.4 (2015): 30-31.
Domino, Edward F. "Indole hallucinogens as animal models of schizophrenia." Animal Models in Human Psychobiology. Springer US, 1976. 239-259.
Filevich, Elisa, et al. "Metacognitive mechanisms underlying lucid dreaming." The Journal of Neuroscience 35.3 (2015): 1082-1088.
Ray, Thomas S. "Psychedelics and the human receptorome." PLoS One 5.2 (2010): e9019.
Halberstadt, Adam L. "Recent advances in the neuropsychopharmacology of serotonergic hallucinogens." Behavioural brain research 277 (2015): 99-120.
Gallimore, Andrew R. "Restructuring consciousness–the psychedelic state in light of integrated information theory." Frontiers in human neuroscience 9 (2015).
Lev‐Ran, Shaul, et al. "Schizophrenia and hallucinogen persisting perception disorder: A clinical investigation." The American Journal on Addictions 24.3 (2015): 197-199.
Greenberg, Mark S., and Martha J. Farah. "The laterality of dreaming." Brain and cognition 5.3 (1986): 307-321.